Dr. John Cush RheumNow
3 years 5 months ago
Pregnancy in PsA
RheumNow Live 2023: Christina Chambers, PhD, MPH, University of California, San Diego School of Medicine
https://t.co/QR0Mb7F1x3 https://t.co/rj6HtoUTpE
Dr. John Cush RheumNow
3 years 5 months ago
JAK inhibitors in Psoriasis and PsA
RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine
https://t.co/eVwQ6ITzD7 https://t.co/GZxVx77aV1
Dr. John Cush RheumNow
3 years 5 months ago
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
Genetic blood tests indicated that BTK and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported.
https://t.co/DMsjFzmjPn https://t.co/X1fg9ylo7g
Dr. John Cush RheumNow
3 years 5 months ago
Study of 481 incident RA:
- no risk of RA w/ tea, alcohol & sugar-soft drinks
- Incr RA risk seen w/ coffee [≥4 vs ≤1cup, HR=1.24;p=0.04] & diet drinks [HR=1.66;never-smokers]
- Reduced RA risk w/ mod EtOH (ever-smokers;HR=0.63) & wine (seropos RA) https://t.co/RQFpxXUT11 https://t.co/ew2imYMLnJ
Dr. John Cush RheumNow
3 years 5 months ago
Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances
This webinar will feature highlights from these lectures followed by live audience Q & A:
-New Therapies for PMR & GCA
-Assessment of GCA and PMR
-GPA Treatment Choices
https://t.co/PRj6QQnxIS https://t.co/Y4aCyTrg0Z
Dr. John Cush RheumNow
3 years 5 months ago
One in Ten has Autoimmune Disease
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
https://t.co/a2VbAO0Fc6 https://t.co/69Yl9OTtKY
Dr. John Cush RheumNow
3 years 5 months ago
Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/Wg3JaTAGf1 https://t.co/Wg3JaTAGf1 https://t.co/iAHfYbZD7t
Dr. John Cush RheumNow
3 years 5 months ago
REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low risk (per/100PY) of serious infections (2.1), H zoster (0.5), & VTE (1.1). Loss of response in 45%, but recaptured 55% w/ dose escalation https://t.co/KgSrKBbv40 https://t.co/M74l4tOA3U
Dr. John Cush RheumNow
3 years 5 months ago
Heart to Heart: Cardiovascular Risk in RA
Tune in to hear experts discuss cardiovascular risk assessment, patient education, and the importance of disease control in the latest therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/Tz8VBiXhwt https://t.co/EQ0dRmM27r
University of Michigan Medical School UMichMedSchool
3 years 5 months ago
When Hannah Glick receives her M.D. this week, she will join her mother, Dr. Rachel Glick, and grandmother, Dr. Marilyn Heins, as the only family in the U.S. with three generations of women doctors that are living, according to @AAMCtoday. https://t.co/AzRw2I4CU8 #GoBlueMed https://t.co/0tgMwVLwxF
Dr. John Cush RheumNow
3 years 5 months ago
View an interactive disease modification patient journey from the #LupusEducatorsNetwork and learn about the importance of helping to prevent renal damage in your patients with #LupusNephritis. #SponsoredbyGSKUSMA
https://t.co/XKG25eVSfa https://t.co/Jbo2iR6OuJ
Dr. John Cush RheumNow
3 years 5 months ago
2010 Colchicine Price Hikes Adversely Affected Gout Care
Research shows that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use,.
https://t.co/WS721SlM6p https://t.co/BBdqDVGolq
Dr. John Cush RheumNow
3 years 5 months ago
Orphan drugs target rare dz <200k. New drugs (2008-2016) compared 5 yr sales 86 orphan Rx to 232 non-orphan = similar sales- Orphan ($719 mill) vs nonorphan ($812 mill). But orphan Rx lower volume offset by higher prices (7X higher) than nonorphan drugs https://t.co/I8kb4A0eyG https://t.co/gEQpssRVkg
Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients. The use of newer b/tsDMARD was hampered by limited efficacy and durability.
